Ismn (Isosorbide Mononitrate)

Ismn belongs to the organic nitrate class and is used in cardiovascular conditions that benefit from vasodilation.

• Prevention of angina pectoris: reduces the frequency and severity of angina attacks.
• Chronic heart failure: improves exercise tolerance and reduces symptoms of dyspnea.
• Ischemic heart disease: helps prevent myocardial ischemia during physical exertion.

• Isosorbide mononitrate is metabolized to release nitric oxide, which activates guanylate cyclase in vascular smooth muscle. The resulting increase in cyclic GMP leads to relaxation of arterial and venous vessels, lowering preload and afterload, and consequently reducing myocardial oxygen demand while improving coronary blood flow.

Ismn may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects

• Headache: mild to moderate, often transient.
• Dizziness or light‑headedness.
• Flushing of the skin.
• Hypotension: especially when standing.
• Nausea or abdominal discomfort.
• Palpitations or tachycardia.

Serious or Rare Side Effects

• Severe hypotension leading to syncope.
• Myocardial infarction in patients with unstable coronary disease.
• Life‑threatening arrhythmias.
• Allergic reactions including rash or angioedema.
• Methemoglobinemia.
• Persistent chest pain despite therapy.

Before initiating Ismn, clinicians should consider several safety measures.

• Blood pressure monitoring: check for orthostatic hypotension.
• Concomitant nitrate use: avoid combined nitrate therapy to prevent excessive vasodilation.
• Phosphodiesterase‑5 inhibitors: do not co‑administer with sildenafil, tadalafil, or similar agents.
• Hepatic impairment: use with caution and consider dose adjustment.
• Renal impairment: monitor renal function and adjust dose if needed.
• Store at ambient temperature: keep in the original pack, protect from moisture.

Ismn can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Other organic nitrates or nitroglycerin: risk of profound hypotension.
• Phosphodiesterase‑5 inhibitors (e.g., sildenafil, tadalafil): may cause severe blood pressure drops.
• Potent antihypertensives (e.g., intravenous nitroprusside): additive hypotensive effect.

Moderate Interactions (Monitor Closely)

• Diuretics: may enhance orthostatic hypotension; monitor electrolytes.
• Beta‑blockers: combined effect on heart rate and blood pressure.
• CYP3A4 inhibitors (e.g., azole antifungals, macrolide antibiotics): may increase plasma levels of isosorbide mononitrate.